ANI Pharmaceuticals (NASDAQ:ANIP) Price Target Raised to $121.00 at HC Wainwright

Key Points

• HC Wainwright raised the price target for ANI Pharmaceuticals from $93.00 to $121.00, indicating a potential upside of 24.81% from the current stock price.
• The company recently announced earnings of $1.80 EPS, exceeding analysts' expectations by $0.38 and reporting a significant 53.2% increase in quarterly revenue year-over-year.
• Insiders sold 412,830 shares of ANI Pharmaceuticals stock worth over $36 million in the last 90 days, with 12.70% of shares currently held by corporate insiders.

ANI Pharmaceuticals (NASDAQ:ANIP - Free Report) had its price objective increased by HC Wainwright from $93.00 to $121.00 in a report issued on Wednesday morning, MarketBeat.com reports. They currently have a buy rating on the specialty pharmaceutical company's stock. HC Wainwright also issued estimates for ANI Pharmaceuticals' Q3 2025 earnings at $1.21 EPS, Q4 2025 earnings at $1.70 EPS, FY2025 earnings at $5.73 EPS and FY2026 earnings at $6.53 EPS.

Other analysts have also issued reports about the company. Piper Sandler restated an "overweight" rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a research note on Friday, August 8th. Guggenheim increased their price target on ANI Pharmaceuticals from $86.00 to $114.00 and gave the stock a "buy" rating in a report on Monday, September 8th. Truist Financial lifted their price target on ANI Pharmaceuticals from $65.00 to $77.00 and gave the stock a "hold" rating in a research note on Monday, August 11th. Zacks Research raised ANI Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Thursday, August 21st. Finally, Wall Street Zen raised shares of ANI Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 16th. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $93.00.

ANI Pharmaceuticals Stock Performance

ANIP stock traded down $0.69 during midday trading on Wednesday, hitting $96.79. 346,251 shares of the stock traded hands, compared to its average volume of 380,949. The firm has a market cap of $2.10 billion, a P/E ratio of -125.70 and a beta of 0.63. ANI Pharmaceuticals has a 1-year low of $52.50 and a 1-year high of $99.50. The stock's fifty day simple moving average is $82.71 and its 200-day simple moving average is $71.06. The company has a debt-to-equity ratio of 1.39, a current ratio of 2.54 and a quick ratio of 1.96.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last issued its earnings results on Friday, August 8th. The specialty pharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.42 by $0.38. ANI Pharmaceuticals had a negative net margin of 1.37% and a positive return on equity of 25.03%. The business had revenue of $211.37 million during the quarter, compared to analysts' expectations of $187.18 million. During the same quarter in the prior year, the business posted $1.02 EPS. The company's revenue for the quarter was up 53.2% on a year-over-year basis. On average, analysts expect that ANI Pharmaceuticals will post 3.86 earnings per share for the current year.

Insider Transactions at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, SVP Chad Gassert sold 20,000 shares of the stock in a transaction on Friday, August 15th. The stock was sold at an average price of $86.97, for a total transaction of $1,739,400.00. Following the transaction, the senior vice president owned 173,226 shares of the company's stock, valued at $15,065,465.22. This represents a 10.35% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Nikhil Lalwani sold 56,960 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $85.93, for a total value of $4,894,572.80. Following the transaction, the chief executive officer owned 411,219 shares of the company's stock, valued at approximately $35,336,048.67. This represents a 12.17% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 412,830 shares of company stock valued at $36,397,254. 11.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of ANIP. Bank of America Corp DE lifted its stake in shares of ANI Pharmaceuticals by 45.1% in the fourth quarter. Bank of America Corp DE now owns 95,160 shares of the specialty pharmaceutical company's stock valued at $5,260,000 after buying an additional 29,584 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of ANI Pharmaceuticals by 3.6% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,523 shares of the specialty pharmaceutical company's stock valued at $582,000 after purchasing an additional 364 shares during the period. ProShare Advisors LLC increased its holdings in shares of ANI Pharmaceuticals by 29.0% during the fourth quarter. ProShare Advisors LLC now owns 6,532 shares of the specialty pharmaceutical company's stock valued at $361,000 after acquiring an additional 1,469 shares in the last quarter. Rafferty Asset Management LLC purchased a new position in shares of ANI Pharmaceuticals during the 4th quarter valued at approximately $200,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of ANI Pharmaceuticals by 41.1% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 47,899 shares of the specialty pharmaceutical company's stock worth $2,648,000 after purchasing an additional 13,948 shares during the last quarter. Institutional investors and hedge funds own 76.05% of the company's stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.